Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 11/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912068 | 1.00 | CHRM2 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3908289 | 1.00 | CHRM2 (0.54) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4682653 | 0.99 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3913264 | 0.99 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3909550 | 0.99 | CHRM2 (0.53) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3909363 | 0.98 | CHRM2 (0.52) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4683817 | 0.96 | CHRM2 (0.48) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4683054 | 0.94 | CHRM2 (0.57) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4683640 | 0.93 | CHRM2 (0.56) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4685845 | 0.92 | CHRM2 (0.59) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | claimed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | claimed |
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-04 | — | — | US | claimed |
| US-7544708-B2 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-06-09 | — | — | US | disclosed |
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | disclosed |
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1551803-B8 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-12-13 | — | — | EP | disclosed |
| EP-1551803-B1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-10-11 | — | — | EP | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| US-20060111425-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-25 | — | — | US | disclosed |
| EP-1551803-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-07-13 | — | — | EP | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005252-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 4/4885CHRM3 1/4885 |
| US-20060111425-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM1 5/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.